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Background: Intrathecal hydrophilic opioids decrease systemic opioid consumption after abdominal surgery and
potentially facilitate enhanced recovery. A meta-analysis is needed to quantify associated risks and benefits.
Methods: A systematic search was performed to find RCTs investigating intrathecal hydrophilic opioids in abdominal
surgery. Caesarean section and continuous regional or neuraxial techniques were excluded. Several subgroup analyses
were prespecified. A conventional meta-analysis, meta-regression, trial sequential analysis, and provision of GRADE
scores were planned.
Results: The search yielded 40 trials consisting of 2500 patients. A difference was detected in ‘i.v. morphine consumption’
at Day 1 {mean difference [MD] 18.4 mg, (95% confidence interval [CI]: 22.3 to 14.4)} and Day 2 (MD 25.5 mg [95%
CI: 30.2 to 20.8]), pain scores at Day 1 in rest (MD 0.9 [95% CI: 1.1 to 0.7]) and during movement (MD 1.2 [95%
CI: 1.6 to 0.8]), length of stay (MD 0.2 days [95% CI: 0.4 to 0.1]) and pruritus (relative risk 4.3 [95% CI: 2.5e7.5]) but
not in nausea or sedation. A difference was detected for respiratory depression (odds ratio 5.5 [95% CI: 2.1e14.2]) but not
when two small outlying studies were excluded (odds ratio 1.4 [95% CI: 0.4e5.2]). The level of evidence was graded as high
for morphine consumption, in part because the required information size was reached.
Conclusions: This study showed important opioid-sparing effects of intrathecal hydrophilic opioids. Our data suggest a
dose-dependent relationship between the risk of respiratory depression and the dose of intrathecal opioids. Excluding
two high-dose studies, intrathecal opioids have a comparable incidence of respiratory depression as the control group.
Clinical trial registration: PROSPERO-registry: CRD42018090682.
Keywords: analgesics; enhanced recovery; intrathecal; laparoscopy; laparotomy; opioids; spinal injectionsEditor’s key points
 In this meta-analysis of 40 studies (2500 subjects), the
authors investigated the analgesia provided following
abdominal surgery by the use of intrathecal hydrophilic
opioids.
 They found that opioid consumption and pain scores
were reduced when intrathecal hydrophilic opioids
were used, while pruritus was increased. LateReceived: 24 February 2020 Accepted: 19 May 2020
© 2020 The Author(s). Published by Elsevier Ltd on behalf of British Journal of A
creativecommons.org/licenses/by/4.0/).
For Permissions, please email: permissions@elsevier.comrespiratory depression occurred more often, but not
when lower doses were used.
 The findings imply that use of low-dose intrathecal
hydrophilic opioids provides analgesic and opioid-
sparing effects in abdominal surgery, and that side-
effects are limited.
 This technique may complement enhanced recovery
programs.naesthesia. This is an open access article under the CC BY license (http://
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2 - Koning et al.Enhanced recovery programs (ERPs) are accompanied by
multiple recommendations, one of which is sufficient post-
operative analgesia.1 A promising analgesic approach is the
use of intrathecal hydrophilic opioids, which have been used
for decades, and renewed interest was caused by a recent
study that was able to show an enhanced recovery in
abdominal surgery.2,3 Still, the risks and benefits need to be
quantified before the widespread use in abdominal surgery
can be advocated.
The benefits of intrathecal hydrophilic opioids, compared
with i. v. administration, are believed to be caused by a higher
potency and a prolonged action, because of a small distribu-
tion volume of the CSF and a slow diffusion, respectively.4
Used as a single bolus technique, intrathecal hydrophilic
opioids have an i. v. opioid-sparing effect, facilitate mobi-
lisation anddbecause of a lack of peripheral vasodilationda
restrictive fluid management can easily be achieved.5 These
properties may lead to a faster recovery after abdominal
surgery.
The risks, however, are pruritus, nausea, and late respira-
tory depression. Especially the fear for the latter has limited
the use of intrathecal hydrophilic opioids. Meylan and col-
leagues 6 performed a meta-analysis regarding intrathecal
morphine, and they found higher rates of pruritus and respi-
ratory depression. However, that meta-analysis involved pre-
dominantly studies in cardiac surgery and a wide range of
dosages were used. This limits the transfer of the found risks
and benefits to abdominal surgery, which requires a meta-
analysis of its own.
Therefore, we performed a meta-analysis to quantify the
risks and benefits of intrathecal hydrophilic opioids. Our study
had two goals: firstly, we set out to identify the studies pub-
lished in the last decade in order to come to an updated
evaluation of the benefits and risks of intrathecal morphine.
Secondly, we focused on a particular patient group (i.e.
abdominal surgery patients undergoing both open and lapa-
roscopic procedures). Furthermore, in recent years trial
sequential analysis (TSA) has emerged as a statistical tech-
nique that maintains the Type 1 error-rate inmeta-analyses at
a prespecified level, which contributes to the certainty of a
conclusion in a meta-analysis.7 This technique was applied to
the data obtained from trials on intrathecal hydrophilic opi-
oids for abdominal surgery.Methods
Our meta-analysis was performed in accordance with the
PRISMA statement.8 The meta-analysis was registered at
PROSPERO with registration number CRD42018090682.
A systemic literature search was performed in December
2019. We searched the databases of Medline, Embase, CINAHL,
LILACS, Cochrane CENTRAL, Web of Science, ClinicalTrials.
gov, and Google Scholar. Filters or language restriction were
not applied. The search combined terms for ‘intrathecal’,
‘hydrophilic opioid’, and ‘abdominal surgery (see
Supplementary material). Morphine, hydromorphone, dia-
morphine, pethidine, and dihydromorphine were considered
hydrophilic opiates. The search was managed with EndNote
and duplicates were removed. Bibliographies of selected
studies were also screened for studies of interest. The search
included trial registers and these records were checked for
completion and publication.
Inclusion and exclusion criteria were defined a priori, and
only randomised trials were considered. The inclusion criteriawere defined according to a PICO-search, in which the Patients
were adults undergoing abdominal surgery, the Intervention
was the administration of intrathecal hydrophilic opioids,
with or without additives, such as local anaesthetics, the
Comparator was analgesia without intrathecal hydrophilic
opioids. The primary outcome measures were i. v. morphine-
equivalents consumption at 24 and 48 h. The secondary
outcome measures were: pain scores in rest and during
movement at 24 and 48 h; time to fit for discharge; length of
hospital stay; time to first analgesic request; intraoperative
sufentanil-equivalent consumption; and incidence of nausea,
pruritus, sedation, and respiratory depression.
Exclusion criteria were Caesarean section and the use of
concomitant continuous regional anaesthesia or neuraxial
anaesthesia.
Two authors (MVK and MK) screened the abstracts for
eligible studies. Full texts of these studies were analysed,
and data were extracted if the study was considered
includable. The extracted data were authors, year of publi-
cation, type of surgery, details of intervention, details of
control, postoperative analgesia, and urinary catheter
management. If the mean and standard deviation were not
reported in the paper, we derived the mean and standard
deviation from the median and range using the formula by
Hozo and colleagues.9 Morphine equivalents were calcu-
lated. The conversion factor for piritramide was 0.7,10 for
papaveretum 0.665,11 for fentanyl 100,12 for pethidine
0.133,13 and for tramadol 0.1.12 The conversion factor to
calculate fentanyl into sufentanil equivalents for intra-
operative analgesia was 0.1.14 If multiple groups with
intrathecal morphine were compared, we combined those
groups and used the mean dose of intrathecal morphine. If a
trial used multiple groups that could serve as control groups
(i.e. without intrathecal hydrophilic opioids), the group with
the control treatment most similar to the intervention group
was used. The continuous outcome measures of such a
study were the mean values of the groups and the largest
standard deviation of the groups. Additions of events and
patients were used for binary data.
Themethodological quality of each study was evaluated by
two authors (MVK and MH) based on the Cochrane Risk of Bias
tool.15 This tool includes assessment of the risks of selection
bias (random sequence generation, allocation concealment),
performance bias (blinding of participant and personnel),
detection bias (blinding of assessor), attrition bias, and other
biases (e.g. multiple treatment groups, comparable baseline
values, and number of participants).
We used Review Manager (RevMan, version 5.1, The Nordic
Cochrane Centre, The Cochrane Collaboration, Copenhagen,
Denmark) for meta-analysis. We considered meta-analyses
worthwhile only if at least three studies with at least 100 pa-
tients per treatment arm were available for analysis. In order
to deal with the expected clinical and methodological het-
erogeneity across studies, a random effects model with in-
verse variance was applied. For dichotomous data, theMantel-
Haenszel-method was used. Risk ratio and 95% confidence
interval (95% CI) were calculated for binary outcome andmean
difference (MD) and 95% CI were calculated for continuous
outcomes. The Peto odds ratio was used to analyse the risk of
respiratory depression, because of the low incidence. The I2
statistic was used to assess heterogeneity and an I2>50% was
considered important heterogeneity.16 A P-value of <0.05 was
taken to indicate statistical significance. We performed the
following prespecified subgroup analyses: laparoscopic
Intrathecal hydrophilic opioids for abdominal surgery - 3surgery, laparotomic surgery, addition of bupivacaine to the
intrathecal hydrophilic opioids, solely intrathecal hydrophilic
opioids, studies with an ERP, and studies with a sham pro-
cedure in the control group for blinding purposes. For the
latter, only studies with a lumbar needle insertion in the
control group, either s. c. or intrathecally and regardless if
medication was administered, were included in this subgroup.
Asymmetry in conventional funnel plots can exist without
true asymmetry, and reasons other than publication bias can
result in asymmetry.17,18 For this reason, contour-enhanced
funnel plots were performed. This was done if there were 10
or more studies in the meta-analyses of the outcomes.15 We
used the test described by Egger and colleagues 19 to test for
plot asymmetry.
We hypothesised that the effect of the dose of intrathecal
opioid could influence the outcome variables. To test for
possible heterogeneity, we performed mixed-effects meta-
regression (unrestricted maximum likelihood) to determine
the effect of the dose of intrathecal opioid. R version 3.1.3 with
the ‘meta’ package (version 4.2e0) and ‘metafor’ package
(version 1.9e7) was used.
Furthermore, similar to interim analyses of primary clin-
ical trials, meta-analyses have been found to be prone to
Type 1 (falsely positive results) and Type 2 error (falsely
negative results) during statistical analysis.20,21. TSA is a
method to avoid Type 1 errors and was performed for the
primary outcomes of our meta-analyses, in order to consider
the risk of random error and better estimate the uncertainty
in our findings.22,23 TSA methodology was described else-
where.24 Sequential monitoring boundaries are made to
decide whether a trial could be terminated early because of a
sufficiently small P-value. When the cumulative z-curve
crosses the monitoring boundaries, an acceptable small
chance of a false-positive result can be assumed. We calcu-
lated the required information size allowing for a Type 1
error of 0.05, and Type 2 error of 0.20, with the MD from the
effect estimate from the conventional random effects
model,25 and heterogeneity estimated by the diversity (D2) in
the included trials. For the analyses we used TSA Viewer
(Version 0.9.5.10 Beta, Copenhagen, Denmark: Copenhagen
Trial Unit, Centre for Clinical Intervention Research, Rig-
shospitalet, 2016).
In order to rate the quality of evidence and strength of
recommendation of our primary outcomes, the Grading of
Recommendations Assessment, Development, and Evaluation
system (GRADE)wasused.26Weassessed the following criteria:
risk of bias, inconsistency, indirectness, imprecision, and
publication bias.When one of the earlier-mentioned itemswas
assessed as a risk, the evidence was downgraded by two levels
(very serious risk) or one level (serious risk). In addition, when
the required informationsizewasnot reachedor the sequential
boundary was not crossed, the evidence was downgraded one
level as well. One of the following four grades was assigned:
high quality (further research is very unlikely to alter the con-
fidence in the estimate of the effect); moderate quality (further
research is likely to alter the confidence in the estimate of the
effect); low quality (further research is very likely to alter the
confidence in the estimate of the effect); or very lowquality (the
confidence in the effect estimate is very little).Results
The flow chart of our literature search is presented in Fig 1. A
total of 40 studies was included in the quantitative analysisand study characteristics are presented in Table 1. Only Child
and Kaufman,37 Day and colleagues,39 and Levy and col-
leagues5 used diamorphine; all others used morphine as
intrathecal opioid. The dose varied between 100 and 800 mg of
morphine and except for two studies that administered a body
weight adjusted dose of 15 mg kg1 and 50 mg kg1
morphine.47,55.
Risk of bias analysis is presented in Fig 2. Main limitations
were allocation concealment and blinding of personnel and
participants.Primary outcomes
Meta-analysis showed an MD in i. v. morphine equivalent
consumption after 24 and 48 h of 18.4 mg (95% CI 22.3
to 14.4) and 25.5 mg (95% CI 30.2 to 20.8), respectively, in
favour of the intrathecal opioids (Fig 3).Secondary outcomes (Table 2)
The pain scores (converted to a range of 0e10) both in rest and
during exertion were reduced in the intrathecal opioid group
after 24 h. The lower pain scores persisted during exertion
after 48 h, but were no longer different in rest. Intraoperative
sufentanil-equivalents consumption was reduced, and time-
to-first analgesic request was prolonged in the intrathecal
opioid group.
No increased risk for nausea or sedation was detected. The
risk for pruritus was increased. Only Boonmak and colleagues
35 reported the incidence of pruritus over different timepoints
during the first two postoperative days, thus no data on
duration and timing could be retrieved. All other studies re-
ported an incidence of pruritus and monitored over 20e48 h.
Because of the heterogeneity in definition of respiratory
depression, only the cases in which medication was admin-
istered or mechanical ventilation was necessary were scored
as respiratory depression in the meta-analysis. An increased
risk for respiratory depression was found between intrathecal
and i. v. opioids (Peto odds ratio 5.49 [95% CI: 2.12e14.24]). The
incidence of respiratory depression was 18/974 in the intra-
thecal opioids group vs 4/888 in the control group. The timing
of respiratory depression after administration of intrathecal
opioids was only reported by Dichtwald and colleagues,41
which was after a mean of 6 h after injection. Licina and col-
leagues55 and Houweling and Joosten47 reported the highest
incidence of respiratory depression with 11/12 patients and 2/
18 patients, respectively. Both studies also used amuch higher
dose of intrathecal morphine than the other studies (15 mg kg1
and 50 mg kg1, respectively, resulting in 1200 mg and 4000 mg in
a 80 kg patient).
However, when those two outlying high-dose studies were
excluded,47,55 the incidence of respiratory depression was 5/
944 for the intrathecal opioids group and 4/858 for the control
group. This led to a Peto odds ratio of 1.39 (95% CI 0.37e5.21).
The length of hospital stay was reduced with an MD of 0.2
days (95% CI 0.4 to 0.1). In addition, patients in the inter-
vention group were earlier fit-for-discharge as well (0.3 days
[95% CI 0.5 to 0.1]).
Management of urinary catheter was reported in 19 studies
(Table 1). The majority inserted a catheter for at least 1 day or
for an unspecified duration. These studies reported no in-
terventions for urine retention after removal of the urinary
catheter. More specifically, the studies that removed the
catheter after 24 h did not report any
Fig 1. Flow diagram of study selection.
4 - Koning et al.recatheterisation,3,5,28,39,61,63 Three studies used no post-
operative urinary catheter, which allowed evaluation for uri-
nary retention.33,44,57 El Sheriff and colleagues44 found no
urinary retention in 50 patients. Beltrutti and colleagues33
found urinary retention in four of seven patients in the
intervention group vs three of nine patients in the control
group, although none required recatheterisation. Motamed
and colleagues57 found four of 17 patients in the intervention
group vs one of 17 patients in the control group with urinary
retention. Of the four of the intervention group, two were
managed with naloxone and two were managed with a uri-
nary catheter.Publication bias
The search included trial registries and yielded 26 trial regis-
trations of which 12 were published and already included. Six
trials were still recruiting. Two trials were completed and
added to the database.38,54 Two other, completed studies were
of potential interest but no publication could be found
(NCT03620916 and NCT03675646).
Contour-enhanced funnel plots were generated and only 24
h i. v. morphine equivalent consumption pain scores in restafter 24 h and time to first analgesic request had Egger tests
with a P-value <0.05 (Fig 4). Asymmetry in the 24 h i. v.
morphine equivalents and pain score in rest after 24 h seemed
to originate from the lack of studies with low standard error
with a large effect size or from the lack of small studies. Based
on visual inspection of the two contour-enhanced funnel
plots, the asymmetry was unlikely to exaggerate the effect
size, which makes a small study effect unlikely. The lack of
studies with a large benefit and a small standard error is un-
likely to be caused by publication bias. Time to first analgesic
request included eight studies, which limits its power. The
funnel plots are presented in the Supplementary material.
Based on these findings, the risk of publication bias seems low.Subgroup analyses (see Supplementary material)
Five subgroup analyses were performed, which were solely
intrathecal hydrophilic opioids, the addition of intrathecal
bupivacaine, laparoscopic surgical procedures, laparotomies,
and studies that involved an ERP. The first four mentioned
subgroups showed no difference to the general comparison
(see Supplementary material). Five studies described use of an
ERP.3,5,38,39,64 In these studies the length of stay was 0.2 days
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Fig 2. Risk of bias assessment for included studies.
8 - Koning et al.(95% CI: 0.5 to 0.1), I2 93%. Fit-for-discharge had too few
subjects (82 vs 84) to produce a reliable analysis. In addition, a
sensitivity analysis was performed including only studies with
a patient-blinding procedure in the control group for the out-
comes ‘pain scores’, morphine consumption, nausea, and
pruritus.3,27,28,32e34,36,44,46,47,49,53e57,59e63 This analysis showed
comparable outcomes to the general comparison.Meta-regression
Meta-regression analyses were performed to detect a dose-
dependent effect in 24 h and 48 h i. v. morphine equivalents
consumption, pain scores in rest and during movement,
nausea, pruritus, sedation, and respiratory depression (see
Supplementary material). The variation in doses was limited
since the most commonly used dose was 300 mg and all but six
studies varied between 100 and 400 mg of intrathecal
morphine. A dose dependency was observed only for pain
scores in rest after 48 h (slope of 0.006/mg morphine [95% CI:
0.001e0.011]) and incidence of pruritus (slope of 0.005/mg
morphine [95% CI: 0.002e0.007]) (see Supplementarymaterial).Trial sequential analysis
TSA showed a required information size of n¼266 for 24 h i. v.
morphine equivalent consumption, n¼103 for 48 h i. v.
morphine equivalent consumption.GRADE recommendations
GRADE recommendations were made for the outcomes ‘i.v.
morphine equivalent consumption after 24 h’, ‘i.v. morphine
equivalent consumption after 48 h’. Inconsistency was
detected, since conventionalmeta-analyses showed an I2>74%
and a P-value for heterogeneity >0.05. The inconsistency was
not explained by subgroup analysis or by different types of
studies since all studies were prospective randomised trials.
Moreover, no studies were in the opposite direction, thus
important clinical inconsistency was deemed unlikely. Since
the CIs of the outcomes were within a clinical useful range, we
did not downgrade the level of evidence because of inconsis-
tency. No publication bias was detected by contour-enhanced
funnel plots and all outcomes were directly measured. The
risk of bias was high because of limited blinding of partici-
pants or outcome assessors in a number of studies, but the
sensitivity analysis of only blinded studies with a sham pro-
cedure did not show different results. Therefore, insufficient
blinding probably had a limited effect and the level of evidence
was not downgraded. The required information size was
reached for both outcomes. Therefore, we graded the out-
comes of 24 and 48 h i. v. morphine equivalent consumption as
a high level of evidence.Discussion
Our meta-analysis of 40 studies including 2500 patients found
a reduced postoperative i. v. morphine equivalent consump-
tion of18.4mg (95% CI22.3 to14.4) in the first 24 and25.5
mg (95% CI 30.2 to 20.8) in the first 48 h in the intrathecal
hydrophilic opioids group. Moreover, we found clinically
relevant reductions by intrathecal hydrophilic opioids for the
following secondary outcomes: pain scores in rest and during
movement after 24 h, pain scores during movement after 48 h,
time to first analgesic request, length of hospital stay, and
Fig 3. Forest plot of (a) morphine-equivalent consumption after 24 h and (b) 48 h. CI, confidence interval; SD, standard deviation.
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Table 2 Summary of the meta-analyses. I2 describes the heterogeneity. RIS, required information size as measured by trial sequential
analysis, Egger test describes the risk for publication bias.
Variable Studies (n) Participants (n) Value (95% CI) I2 (%) RIS Egger test Grade
Benefit Mean difference
Morphine consumption day 1 (mg) 30 1809 18.4 (22.3 to 14.4) 99 266 0.03 High
Morphine consumption day 2 (mg) 22 1309 25.5 (30.2 to 20.8) 97 103 0.21 High
Pain scores in rest, day 1 (NRS) 33 2164 0.9 (1.1 to 0.7) 93 0.03
Pain in exertion, day 1 (NRS) 19 1099 1.2 (1.6 to 0.8) 79 0.79
Pain scores in rest, day 2 (NRS) 19 1114 0.4 (0.7 to 0.1) 97 0.94
Pain in exertion, day 2 (NRS) 13 639 0.4 (0.7 to 0.1) 50 0.14
Intraoperative sufentanil use (mg) 11 625 12.9 (19.3 to 6.5) 91 0.07
Time to first analgesic request (h) 8 309 9.7 (4.9e14.5) 99 0.01
Time to fit-for-discharge (days) 4 233 0.3 (0.5 to 0.1) 28 0.80
Length of hospital stay (days) 17 1416 0.2 (0.4 to 0.1) 88 0.12
Risk Risk ratio
Incidence of nausea 25 1412 1.1 (0.9e1.4) 48 0.12
Incidence of pruritus 23 1282 4.3 (2.5e7.5) 57 0.05
Incidence of sedation 12 644 0.7 (0.5e1.1) 2 0.53
Incidence of respiratory depression 31 1862 5.5 (2.1e14.2) 14 0.17
Incidence of respiratory depression (<500 mg) 26 1473 1.1 (0.2e8.2) 21 N/A
MD, mean difference; 95% CI, 95% confidence interval; NRS, numeric rating scale; RIS, required information size; RR, relative risk.
10 - Koning et al.intraoperative sufentanil equivalent consumption. The risk of
pruritus was increased, and a dose-dependent effect was
found. Overall, the risk of respiratory depression was
increased (Peto odds ratio 5.49 [95% CI: 2.12e14.24]), but when
two outlying studies of doses >1000 mg of intrathecal morphine
were excluded, a similar incidence of respiratory depression
as the control group was found (Peto odds ratio of 1.39 [95% CI
0.37e5.21]). Subgroup analysis for laparoscopic, laparotomic,
addition of bupivacaine, and solely hydrophilic intrathecal
opioids yielded no substantial differences compared with the
total group for all the outcomes.
These results led to different conclusions than the results
of a previous meta-analysis.6 This meta-analysis shows that
the use of intrathecal hydrophilic opioids in abdominal sur-
gery has several benefits including the reduced systemic
opioid consumption, lower pain scores, and a slightly reduced
length of stay. The risks consist mostly of pruritus. Urinary
retention was not evaluated in the majority of the included
trials. The risk of respiratory depression was not increased
when the studies with a dose more than 1000 mg were
excluded. It appeared that a specific indication (i.e. abdominal
surgery), a specific definition of respiratory depression, and
more recent studies led to an acceptable safety profile. While
in the other meta-analysis it was suggested to abandon this
analgesic technique, this study shows the positive effects
may be substantial in abdominal surgery and the risks are
limited.6
The reduction in i. v. morphine equivalents consumption
may not come as a surprise, since this effect has already been
described for many years.65 However, we feel that our finding
of a reduction in postoperative morphine consumption of 18.4
mg (95% CI22.3 to14.4) in the first 24 h is clinically relevant.
In addition, difference in morphine consumption further
increased to 25.5mg (95% CI30.2 to20.8) after 48 h, a finding
that is unique in our study and which was not shown by
Meylan and co-workers.6 These findings are based on suffi-
cient data, as displayed by TSA.
In addition, the mean morphine equivalent consumption
allows a comparison of this method with other opioid-sparing
techniques such as i. v. lidocaine (4.5 mg [95% CI: 6.3to 2.8]),66 high dose pregabalin (13.4 mg [95% CI: 22.8
to 4.0]),67 and ketamine (10.3 [95% CI 13.8 to 6.8]).68 This
is not a direct scientific comparison, so it should be interpreted
with caution, but it may provide an intuitive effect size. Of
importance is that the opioid-sparing effect in our meta-
analysis is in addition to paracetamol and NSAIDs, since
most studies used this medication as a basal multimodal
analgesia regimen. We believe that the use of additional
opioid-sparing strategies, such as intrathecal hydrophilic
opioids, i. v. lidocaine, pregabalin, or ketamine, should be
regarded as addition to the use of paracetamol and NSAIDs,
since these are most consolidated in clinical practice.
This work supports the use of intrathecal hydrophilic opi-
oids within an ERP, since the lower pain scores during move-
ment caused by intrathecal hydrophilic opioids may facilitate
early mobilisation.69 Additionally, other goals such as to
minimise systemic opioids and still produce low pain scores
are achieved as well.70 This mechanism could explain the
reduced postoperative length of stay. In line with previous
research, we interpreted the difference in length of stay as one
out of every five patients leaves the hospital a day earlier,
because in most studies the length of stay was scored per full
day and not in half or quarter days. Still, this outcomemust be
interpreted with caution, because the subgroup analysis of
studies which implemented an ERP did not show any differ-
ence and length of stay may be influenced by non-medical
issues, making fit-for-discharge perhaps a better variable for
reflecting recovery.3
Other studies reported that the use of intrathecal hydro-
philic opioids was associated with adverse effects, such as
urinary retention, pruritus, nausea, and the risk of late respi-
ratory depression.71 By contrast, our meta-analysis was un-
able to detect a difference in nausea. Urinary retentionwas not
measured since the majority of the included studies used an
urinary catheter for at least the first postoperative day. Inter-
estingly, none of these studies reported a case of recatheter-
isation or urinary retention beyond that period.
The most common side-effect of intrathecal hydrophilic
opioids is pruritus and we found a dose-dependent effect for
pruritus in the range of 100e800 mg of intrathecal morphine.
Fig 4. Contour-enhanced funnel plot of A. 24 hour morphine equivalent consumption and B. pain score at rest after 24 hours. NRS, numeric
rating scale.
Intrathecal hydrophilic opioids for abdominal surgery - 11We have to point out that a previous meta-analysis of Meylan
and colleagues6 did not detect a dose-dependent effect,
which may be attributable to the lower number of studies in
that analysis. Studies that have purposely investigated therelationship between the dose and the incidence of pruritus
were able to detect a correlation.72 Theoretically, severe
pruritus might delay hospital discharge, albeit the pruritus
probably lasts shorter than the time for recovery. The
12 - Koning et al.duration of pruritus was only investigated in the study of
Boonmak and colleagues35 over 48 h, which showed a decline
of incidence after 24 h. This is in accordance with other
studies.3,73
Late respiratory depression is an adverse effect of concern
and probably limits the widespread use of intrathecal hydro-
philic opioids.74 Since only one study explicitly investigated
the time to respiratory depression, we are unable to draw
conclusions on this aspect.35 In our analysis we detected
similar incidences of respiratory depression (5/944 for the
intrathecal opioids group and 4/844 in the control group) by
the use of intrathecal opioids in low dosage. This led to a
markedly different conclusion than a previous meta-analysis,
which found 6/504 in the intrathecal morphine group and 0/
440 in the control group. This difference can be explained by a
different definition of respiratory depression, the difference in
dosage, and the different type of surgery (i.e. abdominal vs
cardiac surgery).
The definition of respiratory depression varies amongst
studies, whichmakes the incidence and severity of respiratory
depression less than clear.75 For our analysis, respiratory
depression was only scored when a medical intervention (i.e.
mechanical ventilation or medication) was installed. This is a
high threshold to score respiratory depression, but we believe
that this definition excludes respiratory failure as a result of
other pathology (e.g. atelectasis, diaphragm dysfunction,
pneumothorax, or haemothorax).Meylan and colleagues6 used
a different definition and included patients after cardiac sur-
gery,whohave higher incidences of this type of pathology than
abdominal surgery. Although the upside of a high threshold for
scoring is that only the clinically important respiratory
depression is scored, the downside is the risk of missing res-
piratory depression that does not require a medical interven-
tion, but still may impact the clinical course of the patients.
Gehling and Tryba76 found a dose-dependent effect for
respiratory depression with a cut-off of 300 mg. In our meta-
regression a dose-dependent effect was visible, but the CI
was too wide for statistical significance. In our analysis with
the exclusion of two outlying studies, the incidence of respi-
ratory depression that required a medical intervention was
still similar to the control group. When excluding these two
outlying high-dose studies, themaximumdose included in our
analysis was 800 mg, but themajority of the studies used a dose
less than 500 mg. For safety measures, we would recommend
using doses less than 500 mg, because these doses were pre-
dominantly investigated.
The incidence of respiratory depression in our control
group seems to be in line with reported incidences in patient-
controlled analgesia (PCA) opioids in a Cochrane review.77 Still,
the Cochrane review used a lower threshold for scoring res-
piratory depression, making this comparison to be interpreted
with caution. However, because the incidences of respiratory
depression are likely to be within the same range for low dose
intrathecal morphine as for PCA opioids, we suggest that the
same monitoring as for patients with PCA opioids should be
applied.77,78 The ERAS society recommends this as well.1
Nonetheless, coadministration of benzodiazepines and
routinely administered systemic opioids should be avoided
during the first 24 h, since respiratory depression may occur
because of interaction.79.
This meta-analysis contains a high level of heterogeneity,
which was not explained by the subgroup analysis, meta-
regression, or methodological differences of the included
studies. The differences in type of surgery is a likely cause ofheterogeneity, but further subgroup analysis was not pre-
specified and could increase the chance of a Type 1 error. The
postoperative analgesic regimen consisted in most studies of
paracetamol, NSAID, and PCA opioids, but variation adds to
heterogeneity as well. Still, the CIs are within clinical signifi-
cant limits and the effects of individual studies were pre-
dominantly in the same direction, therefore we did not alter
the GRADE level of evidence based on heterogeneity.
Besides the inherent downside of a meta-analysis by the
methodological limitations of the included studies, an addi-
tional limitation of this study is the probability of missing
studies. We were unable to retrieve a full text of Toǧal and
colleagues.80 Another issue is the low number of patients for
some outcomes. Of importance is the respiratory depression,
for which no increased ratio was found. This too could be
because of the low number of events and patients. Some
outcomes have been reported in dichotomous and continuous
variables, such as patient satisfaction and sedation, which
limited the ability to pool the data. A third limitation is the
pooling of various types of abdominal surgery, which adds to
heterogeneity. We mentioned in the introduction that only
similar types of surgery should be analysed and even though
only abdominal surgery was included, a variance within
abdominal surgery is still expected. Subgroup analyses were
performed to restrict this limitation. Fourth, not all included
studies described characteristics of the recovery phase such as
time to oral feeding, mobilisation, and extent of mobilisation
and therefore no comments regarding this subject can be
made. Finally, high levels of bias for blinding and allocation
concealment in the individual studies cause limitations for the
meta-analysis as well.
In conclusion, intrathecal hydrophilic opioids reduce
intraoperative and postoperative opioid consumption, pain
scores, and length of hospital stay in abdominal surgery.
These properties make it a potentially important contributor
to the overall effects of an ERP, and we feel this technique
should be considered more frequently. The risk for pruritus is
increased in a dose-dependent fashion. In our opinion,
anaesthesiologists are reluctant to administer intrathecal
morphine because of fear of respiratory depression. An
increased incidence of respiratory depression was found, but
this was predominantly caused by two studies using high
doses of intrathecal morphine. When these two studies were
excluded, this rare complication was not more common in the
intervention group than in the control group with systemic
opioids. Still, the majority of the studies used a dose less than
500 mg, thus the evidence is predominantly based on this range
of doses. We recommend taking similar precautions as with
the use of systemically administered opioids for the duration
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